Op-Ed: A Door Opens to Transform Cancer Care Incoming CMS Administrator Chiquita Brooks-LaSure brings hope to the cancer community May 25, 2021
Test Can Predict Death Risk With Adrenal Tumors This can help guide need for surgical intervention, researcher says May 24, 2021
RET Fusion Inhibitor Active Beyond Lung, Thyroid Cancers Responses to selpercatinib in almost half of tumors outside approved indications May 21, 2021
CHS Sues Thousands of Patients; Hospital Parking Fees Under Fire; Trump-Era Emails This past week in healthcare investigations May 19, 2021
Impressive Results With Lenvatinib in Challenging Tumors Multitargeted TKI achieves strong ORR in advanced gastroenteropancreatic NETs May 10, 2021
No Clarity for Role of Laser Therapy in Vulvar Lichen Sclerosus Mixed results from two small randomized clinical trials May 10, 2021
Is Dynamic AFP-R Key to Transplant Selection in Liver Cancer? Dynamic alpha-fetoprotein response improved prediction of patient outcomes May 05, 2021
What's Behind the Mysterious Chest Pain in Bladder Cancer Patient? Cardiomyopathy risks interrupting cancer treatment, worsening prognosis May 03, 2021
'It's a Straw-Man Argument': What We Heard This Week Quotable quotes from 番茄社区app's sources May 02, 2021
FDA Panel Splits on Anti-PD-1 Monotherapy in HCC All thumbs up for pembrolizumab, pending further data, but no such luck for nivolumab Apr 30, 2021
What to Do With a Rare, Aggressive Bladder Cancer Case authors lament scant information on treatments or outcomes Apr 26, 2021
PD-1 Inhibitor Approved for dMMR Endometrial Cancer Dostarlimab led to 42.3% response rate in recurrent/advanced disease Apr 22, 2021
Surveillance Spurned for Small Papillary Thyroid Tumors Nearly all head and neck surgeons would opt for lobectomy or total thyroidectomy Apr 22, 2021
Olympic Gold Medalist Nathan Adrian's Testicular Cancer The swimmer's diagnosis, treatment, and an "extra year" of pandemic prep for Toyko Apr 20, 2021
Another Player in Advanced Bladder Cancer Accelerated FDA approval of sacituzumab govitecan after chemo, immunotherapy Apr 14, 2021
Another FGFR Inhibitor Active in Bile Duct Cancers Clinical benefit rate of 82% in patients selected for FGFR2 fusions, rearrangements Apr 13, 2021
Practice-Changing Results in Metastatic Uveal Melanoma Bispecific T cell-engaging tebentafusp reduces survival hazard by 50% Apr 10, 2021
No Cancer Risk With Commonly Used Blood Pressure Meds Largest analysis yet but definitive data remain elusive Apr 05, 2021
Anti-PD-L1 Flops in Locally Advanced Head and Neck Cancer No PFS benefit from adding avelumab to chemoradiation, hazard ratio favored placebo Apr 02, 2021
A Win for Adjuvant Immunotherapy in Esophageal Cancer And other highlights from the Society of Surgical Oncology's virtual 2021 meeting Mar 31, 2021
Model: Give COVID-19 Vaccine to All Patients Before Surgery Prioritizing surgical patient population could avert more COVID deaths Mar 25, 2021
Op-Ed: Blood Cancer Patients Need More COVID Vax Answers Patients are left wondering, "will I be protected?" Mar 24, 2021
Little Benefit With Adjuvant Therapy for High-Risk Endometrial Cancer Chemo prevented relapse but did not improve survival, no benefit from radiotherapy Mar 23, 2021
Androgen Receptor Inhibitor Active in Endometrial Cancer SGO: Apatinib for platinum-resistant ovarian cancer, pembrolizumab for advanced vulvar cancer Mar 22, 2021
Hormonal IUD Shows Promise in Early Endometrial Cancer Regression seen in 82% of women with precancerous lesions Mar 21, 2021
Practice-Changing Trial in Second-Line Endometrial Cancer Pembrolizumab plus lenvatinib improved median OS by nearly 7 months versus chemotherapy Mar 19, 2021
Class of Cancer Drug Linked to Aneurysms, Artery Dissections Database analysis finds more reports than expected with antiangiogenic drugs Mar 18, 2021
Acupuncture Tops Usual Care for Pain in Cancer Survivors Two types of acupuncture proved superior, with one better than the other Mar 18, 2021
Whole-Genome Sequencing Makes a Case in Leukemia Study More actionable alterations detected in myeloid malignancies versus cytogenetics Mar 10, 2021
New Targeted Therapies Show Promise in Cancer Selected abstracts from the ESMO Targeted Anticancer Therapies virtual meeting Mar 03, 2021
New Standard in High-Risk Muscle-Invasive Bladder Cancer? Adjuvant nivolumab improves DFS in all comers, PD-L1 population Feb 13, 2021
Survival Boost in Bladder Cancer With Antibody-Drug Conjugate Four-month absolute improvement with enfortumab vedotin in previously treated disease Feb 12, 2021
AGA Updates Guidelines for Refractory H. Pylori New info stresses knowing patients' antibiotic exposure and doing drug susceptibility testing Feb 01, 2021
First-Ever Survival Bump in Relapsed Mesothelioma OS, PFS improved with nivolumab, but questions remain about alternatives, biomarkers Jan 30, 2021
JAK Inhibitor Misses Endpoint in Safety Study. Now What? Major blow to popular class of oral rheumatology drugs Jan 27, 2021
Montana Oncologist Fired for Misdiagnosing, Overtreating Patients But some rally around him Jan 26, 2021
Telehealth's Security Problem; Virtual Cancer Care; Post-Pandemic Teladoc Emerging trends in telemedicine and telehealth Jan 25, 2021
Ozempic Seeking High Dose OK; Thyroid Cancer Overdiagnosed in Kids? News and commentary from the endocrinology world Jan 24, 2021
Cancer and COVID; Booze and Cancer; 'Screech' Starts Chemo News, features, and commentary about cancer-related issues Jan 21, 2021
Preop RT Flunks Test in Borderline Pancreatic Cancer Chemotherapy alone judged efficacious but not chemoradiation Jan 20, 2021
